{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T01:55:47Z","timestamp":1782266147889,"version":"3.54.5"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec id=\"ab-doi230040-4\"><jats:title>Importance<\/jats:title><jats:p>Autoimmune bullous diseases (AIBDs) are chronic relapsing-remitting conditions with significant morbidity. Skin-related quality of life (SRQL) may vary by AIBD subtype and disease type. Disease severity and flare severity can be difficult to define; SRQL can offer a key insight.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-5\"><jats:title>Objectives<\/jats:title><jats:p>To investigate the Skindex-16 score as an SRQL measure in AIBD subtypes during flare and nonflare states and to evaluate Skindex-16 construct validity.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cross-sectional study was conducted from September 1, 2016, to February 1, 2020, among 192 patients at the University of Utah Health autoimmune dermatology clinic with pemphigoid, pemphigus, dermatitis herpetiformis, and linear immunoglobulin A disease. Patients had an encounter-associated diagnosis, Skindex-16 scores, and self-reported flare status. Statistical analysis was performed from March 2022 to June 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-7\"><jats:title>Exposure<\/jats:title><jats:p>Autoimmune bullous disease subtype and patient-reported flare status.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Skindex-16 domain scores (emotions, symptoms, and functioning; range, 0-100, where 0 indicates no effect on SRQL and 100 maximum effect) and individual item scores were described by disease and flare status. Flare scores were expected to be higher by at least the standard error of measurement (SEm). Convergent validity was assessed using Spearman correlation among Skindex-16 scores, serologic titers, and other patient-reported outcome measures. Floor or ceiling domain scores (&amp;amp;lt;20% of sample scoring either lowest or highest possible domain scores, respectively) were assessed for Skindex-16. Structural validity was assessed using confirmatory factor analysis (CFA).<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-9\"><jats:title>Results<\/jats:title><jats:p>The study included 192 patients with 212 visits (median age, 68 years [IQR, 58-76 years]; 123 of 212 women [58.0%]) with Skindex-16 scores (64 in flare state and 148 in nonflare state). Median Skindex-16 domain scores were higher for all disease categories among patients in the flare state compared with those in the nonflare state (pemphigoid [emotions: flare, 52.4 (IQR, 38.1-69.0); nonflare, 7 (IQR, 0-17); symptoms: flare, 37.5 (IQR, 29.2-58.0); nonflare, 13 (IQR, 0-25); functioning: flare, 26.7 (IQR, 10.0-56.7); nonflare, 0 (IQR, 0-3)]; pemphigus [emotions: flare, 54.8 (IQR, 31.0-81.0; nonflare, 0 (IQR, 0-19); symptoms: flare, 58.3 (IQR, 41.7-70.8); nonflare, 4 (IQR, 0-12.5); functioning: flare, 26.7 (IQR, 13.3-83.3); nonflare, 0 (IQR, 0-3.33)]; dermatitis herpetiformis [emotions: flare, 72.6 (IQR, 34.7-90.5); nonflare, 14.3 (IQR, 2.4-26.2); symptoms: flare, 69 (IQR, 31.3-85.4); nonflare, 12.5 (IQR, 0-29.2); functioning: flare, 38.3 (IQR, 5.0-63.2); nonflare, 0 (IQR, 0-13.3)]. This difference exceeded SEm cut points. Cronbach \u03b1 was greater than 0.80 for all domains and AIBDs. Moderate or low correlations were seen with desmoglein 1 and bullous pemphigoid 180 titers. Moderate correlation existed between Skindex-16 and Patient-Reported Outcomes Measurement Information System Depression scores (emotions: \u03c1\u2009=\u20090.40; symptoms: \u03c1\u2009=\u20090.41; functioning: \u03c1\u2009=\u20090.48), and strong correlation existed between Skindex-16 and patient-reported disease severity (emotions: \u03c1\u2009=\u20090.71; symptoms: \u03c1\u2009=\u20090.73; functioning: \u03c1\u2009=\u20090.66). Floor domain scores greater than 20% were seen among patients in the nonflare state, but ceiling domain scores were rare (&amp;amp;lt;10% for all domains); CFA model fit was poor.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230040-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this cross-sectional study, SRQL was highly associated with flare of AIBDs. Skin-related quality of life was worse during periods without flare among patients with pemphigoid and dermatitis herpetiformis compared with pemphigus, highlighting residual SRQL morbidity. Skindex-16 showed good construct validity, but the poor CFA model fit needs further research. Clinical measurement of SRQL in AIBDs can add critical disease-severity information.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.3121","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T15:06:44Z","timestamp":1694617604000},"page":"1185","source":"Crossref","is-referenced-by-count":11,"title":["Skin-Related Quality of Life During Autoimmune Bullous Disease Course"],"prefix":"10.1001","volume":"159","author":[{"given":"Zachary H.","family":"Hopkins","sequence":"first","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"},{"name":"Department of Dermatology, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanina L.","family":"Taliercio","sequence":"additional","affiliation":[{"name":"Division of Medical Genetics, Department of Pediatrics, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie T.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Hull","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L. W.","family":"Rhoads","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Zone","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram N.","family":"Sahni","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Kean","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City"},{"name":"Division of Health System Innovation and Research, University of Utah, Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Secrest","sequence":"additional","affiliation":[{"name":"Autoimmune Dermatology Clinic, University of Utah Health, Salt Lake City"},{"name":"Department of Population Health Sciences, University of Utah, Salt Lake City"},{"name":"Department of Dermatology, Te Whatu Ora\u2013Waitaha Canterbury (Health New Zealand), Christchurch, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi230040r1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/jalm\/jfab147","article-title":"Diagnostics for dermatologic diseases with autoantibodies.","volume":"7","author":"Leiferman","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"2","key":"doi230040r2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.","volume":"136","author":"Schmidt","year":"2000","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi230040r3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5021\/ad.2012.24.1.45","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid.","volume":"24","author":"Lee","year":"2012","journal-title":"Ann Dermatol"},{"issue":"12","key":"doi230040r4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/sj.jid.5701142","article-title":"Critical review of generic and dermatology-specific health-related quality of life instruments.","volume":"127","author":"Both","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi230040r5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.det.2011.03.009","article-title":"Pemphigus and quality of life.","volume":"29","author":"Chee","year":"2011","journal-title":"Dermatol Clin"},{"issue":"2","key":"doi230040r6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/jde.2012.39.issue-2","article-title":"Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires.","volume":"39","author":"Ghodsi","year":"2012","journal-title":"J Dermatol"},{"key":"doi230040r7","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.3389\/fimmu.2019.02571","article-title":"Assessing the correlation between disease severity indices and quality of life measurement tools in pemphigus.","volume":"10","author":"Krain","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"doi230040r8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ajp.2012.10.005","article-title":"Psychiatric morbidity in pemphigus and psoriasis: a comparative study from India.","volume":"6","author":"Kumar","year":"2013","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"doi230040r9","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/ced.2012.37.issue-6","article-title":"Quality of life in patients with pemphigus receiving adjuvant therapy.","volume":"37","author":"Paradisi","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"doi230040r10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaad.2008.09.014","article-title":"Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools.","volume":"60","author":"Paradisi","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi230040r11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1590\/abd1806-4841.20153372","article-title":"Quality of life index in autoimmune bullous dermatosis patients.","volume":"90","author":"Penha","year":"2015","journal-title":"An Bras Dermatol"},{"issue":"1","key":"doi230040r12","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.12788\/cutis","article-title":"Bullous dermatoses and quality of life: a summary of tools to assess psychosocial health.","volume":"109","author":"Riopelle","year":"2022","journal-title":"Cutis"},{"issue":"9","key":"doi230040r13","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire in the USA.","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"issue":"3","key":"doi230040r14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts.","volume":"82","author":"Murrell","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi230040r15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/bjd.v183.5","article-title":"Sensitivity to change and correlation between the autoimmune bullous disease quality-of-life questionnaires ABQOL and TABQOL, and objective severity scores.","volume":"183","author":"Ferries","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230040r16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores.","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi230040r17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2340\/00015555-1666","article-title":"Clinical significance of anti\u2013desmoglein-1 and -3 circulating autoantibodies in pemphigus patients measured by area index and intensity score.","volume":"94","author":"Patsatsi","year":"2014","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"doi230040r18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1111\/bjd.2013.169.issue-5","article-title":"The development and validation of the treatment of Autoimmune Bullous Disease Quality of Life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease.","volume":"169","author":"Tjokrowidjaja","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi230040r19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jaad.2020.05.161","article-title":"Subepithelial autoimmune bullous dermatoses disease activity assessment and therapy.","volume":"85","author":"Montagnon","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi230040r20","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jclinepi.2015.03.023","article-title":"Pragmatic characteristics of patient-reported outcome measures are important for use in clinical practice.","volume":"68","author":"Kroenke","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"doi230040r21","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s11136-021-03030-w","article-title":"Clinicians\u2019 perspectives on the integration of electronic patient-reported outcomes into dermatology clinics: a qualitative study.","volume":"31","author":"Taliercio","year":"2022","journal-title":"Qual Life Res"},{"issue":"4","key":"doi230040r22","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/bjd.2012.166.issue-4","article-title":"Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis.","volume":"166","author":"Fernandez-Pe\u00f1as","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi230040r23","doi-asserted-by":"publisher","first-page":"adv00105","DOI":"10.2340\/00015555-3417","article-title":"\u201cDLQI seems to be \u2018action\u2019, and Skindex-29 seems to be \u2018emotion\u2019\u201d: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures.","volume":"100","author":"Paudyal","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"doi230040r24","doi-asserted-by":"publisher","author":"Szab\u00f3","journal-title":"Br J Dermatol","DOI":"10.1111\/bjd.v186.3"},{"key":"doi230040r25","doi-asserted-by":"publisher","author":"Dan","journal-title":"Br J Dermatol","DOI":"10.1093\/bjd\/ljad133"},{"issue":"2","key":"doi230040r26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life.","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"issue":"5","key":"doi230040r27","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi230040r28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaad.2022.01.016","article-title":"Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: a French multicenter retrospective study.","volume":"86","author":"Battesti","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi230040r29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol"},{"issue":"4","key":"doi230040r30","first-page":"272","article-title":"Anti-BP180 and anti-BP230 enzyme-linked immunosorbent assays for diagnosis and disease activity tracking of bullous pemphigoid: a prospective cohort study.","volume":"39","author":"Chanprapaph","year":"2021","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"doi230040r31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol"},{"issue":"1","key":"doi230040r32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamadermatol.2013.5757","article-title":"Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study.","volume":"150","author":"Fichel","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi230040r33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230040r34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts.","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230040r36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/00273171.2022.2163476","article-title":"dynamic: an R package for deriving dynamic fit index cutoffs for factor analysis.","volume":"58","author":"Wolf","year":"2023","journal-title":"Multivariate Behav Res"},{"issue":"8","key":"doi230040r37","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2340\/16501977-0119","article-title":"Interpreting rehabilitation outcome measurements.","volume":"39","author":"Jette","year":"2007","journal-title":"J Rehabil Med"},{"issue":"2","key":"doi230040r38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/09546634.2012.681016","article-title":"Validation of the Skindex-16 questionnaire in patients with skin diseases in Morocco.","volume":"25","author":"El Fakir","year":"2014","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi230040r39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12955-017-0610-3","article-title":"Psychometric properties of the Press Ganey Outpatient Medical Practice Survey.","volume":"15","author":"Presson","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"doi230040r40","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.jid.5700212","article-title":"Testing and reducing Skindex-29 using Rasch analysis: Skindex-17.","volume":"126","author":"Nijsten","year":"2006","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi230040r41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1177\/120347540100500202","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"doi230040r42","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/bjd.v186.3","article-title":"A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI-Relevant and Skindex-16.","volume":"186","author":"Szab\u00f3","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi230040r43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamadermatol.2018.5655","article-title":"Influence of \u201cnot relevant\u201d responses on the Dermatology Life Quality Index (DLQI) for patients with psoriasis in the United States.","volume":"155","author":"Barbieri","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi230040r44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jdv.2012.27.issue-1","article-title":"Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.","volume":"27","author":"He","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi230040r45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bjd.v184.1","article-title":"Evaluation of \u201cnot relevant\u201d responses on the Dermatology Life Quality Index (DLQI) and the DLQI-R scoring modification among Indian patients with vitiligo.","volume":"184","author":"Gupta","year":"2021","journal-title":"Br J Dermatol"},{"key":"doi230040r46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12955-016-0419-5","article-title":"Rasch analysis holds no brief for the use of the Dermatology Life Quality Index (DLQI) in Chinese neurodermatitis patients.","volume":"14","author":"Liu","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"doi230040r47","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/jdv.2018.32.issue-5","article-title":"A detailed analysis of \u201cnot relevant\u201d responses on the DLQI in psoriasis: potential biases in treatment decisions.","volume":"32","author":"Rencz","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi230040r48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/jid.2011.354","article-title":"Dermatology Life Quality Index: time to move forward.","volume":"132","author":"Nijsten","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi230040r49","doi-asserted-by":"publisher","first-page":"284","DOI":"10.2340\/00015555-0075","article-title":"Dimensionality of the Dermatology Life Quality Index (DLQI): a commentary.","volume":"86","author":"Nijsten","year":"2006","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi230040r50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamadermatol.2013.8179","article-title":"Scoring systems for blistering diseases in practice: why bother, and which one should you use?","volume":"150","author":"Murrell","year":"2014","journal-title":"JAMA Dermatol"},{"key":"doi230040r51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1741-7015-9-86","article-title":"Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science.","volume":"9","author":"McKenna","year":"2011","journal-title":"BMC Med"},{"issue":"24","key":"doi230040r52","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris.","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"doi230040r53","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1111\/jdv.v36.10","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi230040r54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11136-008-9430-6","article-title":"The applications of PROs in clinical practice: what are they, do they work, and why?","volume":"18","author":"Greenhalgh","year":"2009","journal-title":"Qual Life Res"},{"issue":"1","key":"doi230040r55","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s41687-018-0061-6","article-title":"How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? a realist synthesis.","volume":"2","author":"Greenhalgh","year":"2018","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"doi230040r56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJMp1109283","article-title":"Shared decision making\u2014pinnacle of patient-centered care.","volume":"366","author":"Barry","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"doi230040r57","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"doi230040r58","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/ijd.2008.47.issue-3","article-title":"Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.","volume":"47","author":"Feng","year":"2008","journal-title":"Int J Dermatol"},{"issue":"5","key":"doi230040r59","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.4317\/jced.56289","article-title":"Evaluation of desmoglein 1 and 3 autoantibodies in pemphigus vulgaris: correlation with disease severity.","volume":"12","author":"Delavarian","year":"2020","journal-title":"J Clin Exp Dent"},{"issue":"6","key":"doi230040r60","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1177\/0961203321999724","article-title":"Differences in quality of life in patients with cutaneous lupus erythematosus with varying income levels.","volume":"30","author":"Joseph","year":"2021","journal-title":"Lupus"},{"issue":"2","key":"doi230040r61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.anclin.2020.01.012","article-title":"Role of gender and race in patient-reported outcomes and satisfaction.","volume":"38","author":"Kozlov","year":"2020","journal-title":"Anesthesiol Clin"},{"key":"doi230040r62","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1472-6963-12-89","article-title":"The influence of age, gender and socio-economic status on multimorbidity patterns in primary care: first results from the MultiCare Cohort Study.","volume":"12","author":"Sch\u00e4fer","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"doi230040r63","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12939-015-0142-6","article-title":"Social inequalities in patient-reported outcomes among older multimorbid patients\u2014results of the MultiCare Cohort Study.","volume":"14","author":"von dem Knesebeck","year":"2015","journal-title":"Int J Equity Health"},{"key":"doi230040r64","doi-asserted-by":"publisher","year":"2019","journal-title":"BMC Public Health","DOI":"10.1186\/s12889-019-7775-0"},{"key":"doi230040r35","volume-title":"Patient-Reported Outcomes: Measurement, Implementation and Interpretation","author":"Cappelleri","year":"2014"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2809082\/jamadermatology_hopkins_2023_oi_230040_1699989208.79688.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:03:00Z","timestamp":1700064180000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2809082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.3121","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}